Investor Relations
Invest in the Future of Bone Health
Join the revolution in ultrasound diagnostics. REMS technology, 35+ revenue streams, franchise-ready model. $1.6M Year 1 → $58M Year 5 with 41% EBITDA margin.
Company Overview
Hallē Health at a Glance
Company Details
Investment Structure
Instrument
SAFE Note @ $5M pre-money, 20% discount
Regulation
Reg CF
Minimum
$5,000
TAM
$15B+
Global bone health market (devices + services + supplements)
SAM
$3.2B
US bone screening + monitoring + supplements
SOM
$180M
Year 5 target with 60+ locations + franchise network
Key Milestones
2021
Founded BioX Unlimited LLC
2023
First REMS device operational
2024
Opened Strength Lab Plus studio, Naples FL
2024
Siemens Healthineers reseller agreement
2025
6 active locations (5 FL + 1 CA). 40+ providers in pipeline.
2026
Rebranded to Halle Health Co. Angel Round opens.
2028
Round 2 — Exclusive investment pool for Round 1 investors
2030
IPO target — Series A institutional round
By the Numbers
Traction at a glance
4,000+
Scans Completed
~1,000
Active Clients
30:1–51:1
LTV:CAC
$762.88
Blended ARPC
85-90%
Gross Margin
6
Locations
The Problem
Bone health screening is broken
of at-risk patients are never screened for bone density issues
the current standard is an X-ray method that measures only density — missing bone quality entirely
average wait time for results with traditional screening methods
Our Solution
REMS: The next generation
Ultrasound
REMS uses ultrasound-based technology, safe for repeat assessments.
Comprehensive Results
Measures bone density, quality, fragility score, and 5-year fracture risk — all in one 15-minute scan.
Same-Day Insights
Clients walk away with results the same day. No waiting weeks for a report.
Scalable Model
Franchise-ready "business in a box" — asset-light expansion through partner network.
Financial Projections
5-Year P&L Summary
Revenue growing from $1.6M to $58.1M with EBITDA margins expanding from 22% to 41% as the platform scales.
| Metric | Year 1 (2026) | Year 2 (2027) | Year 3 (2028) | Year 4 (2029) | Year 5 (2030) |
|---|---|---|---|---|---|
| Operating Metrics | |||||
| Network Locations | 9 | 26 | 56 | 101 | 171 |
| Annual Scans | 1,315 | 4,800 | 12,000 | 26,400 | 54,000 |
| Active Providers | 10 | 30 | 60 | 100 | 160 |
| Subscribers | 144 | 600 | 1,800 | 4,500 | 10,000 |
| Revenue | |||||
| Direct Scan Revenue | $610K | $2.2M | $5.6M | $12.2M | $25.1M |
| Subscriptions | $120K | $480K | $1.4M | $3.6M | $8.0M |
| Provider Network | $394K | $1.2M | $2.5M | $4.2M | $7.2M |
| Franchise Revenue | $293K | $986K | $2.2M | $4.2M | $7.4M |
| Marketplace | $85K | $340K | $900K | $2.1M | $4.5M |
| Affiliate & Partners | $65K | $250K | $600K | $1.2M | $2.4M |
| Content Platform | $12K | $60K | $200K | $500K | $1.2M |
| Waitlist & Events | $25K | $80K | $200K | $450K | $900K |
| Other | $0 | $50K | $200K | $600K | $1.5M |
| Total Revenue | $1.6M | $5.7M | $13.8M | $29.1M | $58.1M |
| Expenses | |||||
| COGS | $561K | $1.8M | $4.0M | $8.1M | $15.1M |
| Technology | $241K | $795K | $1.5M | $2.6M | $4.7M |
| Marketing | $257K | $908K | $2.1M | $4.1M | $7.6M |
| Operations | $192K | $681K | $1.7M | $3.5M | $7.0M |
| Total Expenses | $1.3M | $4.2M | $10.3M | $18.3M | $34.3M |
| EBITDA | $353K | $1.5M | $3.6M | $10.8M | $23.8M |
| EBITDA Margin | 22% | 26% | 26% | 37% | 41% |
Growth Trajectory
Quarterly revenue & key metrics
Quarterly Revenue
| Year | Q1 | Q2 | Q3 | Q4 | Annual | YoY |
|---|---|---|---|---|---|---|
| Year 1 (2026) | $195K | $310K | $420K | $540K | $1.5M | — |
| Year 2 (2027) | $620K | $750K | $870K | $1.0M | $3.2M | 121% |
| Year 3 (2028) | $1.1M | $1.3M | $1.5M | $1.7M | $5.6M | 73% |
| Year 4 (2029) | $1.9M | $2.1M | $2.4M | $2.7M | $9.1M | 62% |
| Year 5 (2030) | $2.9M | $3.3M | $3.7M | $4.1M | $14.0M | 55% |
Key Growth Metrics
Total Clients
Locations
Active Providers
Subscribers
Countries
Vendors
Monthly Rev (Dec)
Rev / Employee
Franchise Model
Hallē License — Business in a Box
Scalable franchise model enabling rapid geographic expansion without capital-heavy owned locations. Each franchise generates ~$98K/yr for Hallē.
Setup Deposit
$30K
One-time franchise fee
Monthly Fee
$99
Platform access fee
Revenue Share
30%
Of scan revenue
Annual to Hallē
$98K
Per franchise per year
Per Franchise Economics
Avg Scans/mo
40
Avg Scan Price
$464
Monthly Gross
$18,560
Hallē Monthly
$5,667
Franchise Growth Projections
| Period | New | Total | Setup Deposits | Platform Fees | Rev Share | Total Revenue |
|---|---|---|---|---|---|---|
| Year 1 | 3 | 3 | $90K | $4K | $200K | $293K |
| Year 2 | 8 | 11 | $240K | $13K | $733K | $986K |
| Year 3 | 15 | 26 | $450K | $31K | $1.7M | $2.2M |
| Year 4 | 25 | 51 | $750K | $61K | $3.4M | $4.2M |
| Year 5 | 40 | 91 | $1.2M | $108K | $6.1M | $7.4M |
| Year 7 | 80 | 211 | $2.4M | $251K | $14.1M | $16.7M |
| Year 10 | 150 | 511 | $4.5M | $607K | $34.0M | $39.1M |
Unit Economics
The numbers behind the growth
Industry-leading customer economics powered by organic acquisition, a waitlist-to-scan engine, and high lifetime value from multi-product engagement.
Weighted Avg Scan
$464.20
80% Bundle ($499) / 20% Full Picture ($325)
Blended ARPC
$762.88
Annual Revenue Per Client across all channels
CAC
$45–75
Customer acquisition cost via digital + waitlist engine
LTV (3yr)
$2,289+
Lifetime value: 4 scans × $430 + subs + marketplace
LTV:CAC
30:1 – 51:1
Industry-leading ratio driven by organic acquisition
Gross Margin
85-90%
Per location (day-rental model, ~$100/day)
Break-Even
1 scan/day
Single scan covers daily location rental cost
Payback
<1 month
CAC recovered on first scan visit
Waitlist-to-Scan Engine
Our proprietary acquisition model converts local demand into booked scans. Clients join a free waitlist in their area. When 45 people sign up, we trigger a pop-up scanning event. 80% convert from waitlist to scan, and 15% upgrade to annual monitoring plans.
80%
Waitlist → Scan
15%
Scan → Annual
B2C Economics
$464.20
Weighted avg scan price (80% bundle / 20% basic)
B2B Economics
$98K/yr
Revenue per franchise license ($30K setup + $99/mo + 30% rev share)
Location Economics
$100/day
Rental cost — 1 scan/day = break-even, 85-90% gross margin
Competitive Landscape
How hallē compares
The only platform combining ultrasound REMS scanning with a full consumer wellness ecosystem — marketplace, provider network, franchise model, and annual monitoring.
| Company | Technology | Bone Quality | Platform | Pricing |
|---|---|---|---|---|
| hallē health | REMS (Echolight) | $325–$499 + subs | ||
| Hologic (DEXA) | Dual X-ray | $100–350 (insurance) | ||
| GE Healthcare | DEXA | $100–350 (insurance) | ||
| BeamMed (Sunlight) | Quantitative US | $50–150 | ||
| BoneForte | REMS (Echolight) | $250–400 | ||
| StrengthX | REMS + BioDensity | $200–350 | ||
| OsteoScan USA | REMS | $250–350 |
Competitive Moats
Only REMS + Full Platform
No competitor offers REMS scanning + marketplace + subscriptions + provider network + education in one ecosystem
Franchise-Ready Model
Hallē License allows rapid scaling without capital-heavy owned locations — unique in bone health
Multi-Sided Revenue
35+ revenue streams vs competitors with 1-2 streams (scan or hardware sales)
Data Network Effects
Every scan builds the largest ultrasound bone health dataset — AI/ML insights platform moat
NASA + Echolight + Siemens
Partnership ecosystem validates technology and opens enterprise/government channels
Content & Community
Premium education, author platform, and community subscriptions create recurring engagement
Low Fixed Costs
Day-rental model ($100/day) vs. traditional $10K-50K/mo clinic leases = 10x capital efficiency
Market Opportunity
Global DEXA Device Market
$656.7M (2024)
→ $1.43B (2034)
8.1% CAGR
Bone Density Testing Services
$1.75B (2022)
→ $2.85B (2030)
6.2% CAGR
Bone Health Supplements
$13.8B (2024)
→ $23.1B (2034)
5.3% CAGR
Global Opportunity
Provider market analysis — 14 countries
A 200M+ at-risk population across 4.6B people, with significant screening gaps in developing markets.
Total Population
4.6B
At Risk
200M+
Target Providers (5yr)
198
Est. Revenue (10yr)
$15.4M
| Country | Pop (M) | Over 50 (M) | DXA/1M | Clinics | Prevalence | Maturity | Opportunity | 5yr Target | 10yr Target | Est. Rev (10yr) |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 335 | 120 | 25-30 | 50,000+ | 10M diagnosed / 44M at risk | Mature | HIGH | 50 | 200 | $13.3M |
| Canada | 40 | 14 | ~20 | 5,000+ | 2.3M affected | Mature | HIGH | 10 | 40 | $2.7M |
| United Kingdom | 67 | 24 | 11-15 | 8,000+ | 3.5M affected | Mature | HIGH | 15 | 120 | $8.0M |
| Germany | 84 | 32 | 15-20 | 12,000+ | 6.3M affected | Mature | MODERATE | 12 | 120 | $8.0M |
| Italy | 59 | 23 | 15-20 | 10,000+ | 5M affected (Echolight HQ) | Mature | HIGH | 10 | 120 | $8.0M |
| Japan | 125 | 52 | 12-18 | 15,000+ | 13M affected | Mature | HIGH | 15 | 60 | $4.0M |
| Australia | 26 | 9 | 20-25 | 4,000+ | 1.2M affected | Mature | HIGH | 8 | 30 | $2.0M |
| South Korea | 52 | 18 | 15-24 | 8,000+ | 5M at risk | Mature | MODERATE | 10 | 60 | $4.0M |
| UAE | 10 | 2 | 5-10 | 1,500+ | Growing awareness | Emerging | HIGH | 8 | 40 | $2.7M |
| Saudi Arabia | 36 | 8 | 3-8 | 2,000+ | 6M at risk | Emerging | HIGH | 8 | 40 | $2.7M |
| Brazil | 215 | 55 | 2-5 | 8,000+ | 10M affected | Developing | VERY HIGH | 10 | 50 | $3.3M |
| Mexico | 130 | 30 | 2-4 | 4,000+ | 4M affected | Developing | HIGH | 5 | 50 | $3.3M |
| India | 1,440 | 300 | <1 | 12,000+ | 61M affected | Early | EXTREME | 8 | 40 | $2.7M |
| China | 1,425 | 400 | <1 | 20,000+ | 90M affected | Developing | EXTREME | 8 | 50 | $3.3M |
| Total | 4,592 | 1,181 | 180,000+ | 198 | 660 | $15.4M | ||||
Investment Structure
Three rounds. One vision.
Our structured investment approach rewards early believers and builds toward a transformative exit.
Round 1
Angel Round
Blind Crowdfunding / SAFE
Who: Open to everyone — accredited and non-accredited investors worldwide
Earliest entry at lowest valuation. 20% discount on next round. Exclusive access to Round 2.
Round 2
Seed Round
Exclusive Investment Pool
Who: Exclusive to Round 1 investors — proportional to initial contribution
8% annual cumulative dividends. Preferred stock with liquidation preference. Pro-rata rights.
Round 3
Series A
Institutional Round
Who: VC funds, family offices, angel groups, and accredited individual investors
Board representation potential. Anti-dilution protection. Clear path to IPO.
Investment Calculator
Model your potential returns
Three scenarios based on compound annual growth rate (CAGR). Hover over the chart to see exact values for each year. Round 1 (Angel/SAFE) does not include dividends.
SAFE (Simple Agreement for Future Equity) • 2026 — 2028 (2 years)
$37K
$48K
$73K
Projected Value Over 5 Years
Note how sharply the curves diverge — this illustrates the inherent uncertainty and range of outcomes in early-stage investing.
Year-by-Year Breakdown
| Year | Pessimistic (8%) | Average (14%) | Optimistic (24%) |
|---|---|---|---|
| Today | $25,000 | $25,000 | $25,000 |
| Year 1 | $27,000 | $28,500 | $31,000 |
| Year 2 | $29,160 | $32,490 | $38,440 |
| Year 3 | $31,493 | $37,039 | $47,666 |
| Year 4 | $34,012 | $42,224 | $59,105 |
| Year 5 | $36,733 | $48,135 | $73,291 |
| Profit | +$11,733 | +$23,135 | +$48,291 |
Methodology & Assumptions
- CAGR model: (Final Value / Investment) ^ (1/years) - 1
- Pessimistic: 8% — comparable to bond/index returns
- Average: 24% — strong health-tech startup growth
- Optimistic: 40% — exceptional early-stage performance
- S&P 500 benchmark: ~10% annual average for reference
These projections are illustrative estimates only based on compound annual growth rate modeling. They do not guarantee future performance. Actual results may vary materially. Early-stage investing carries substantial risk including total loss of investment. See Investment Disclaimer for full risk disclosures.
Platform Readiness
What's built & what's next
Our platform is operational with core services live. Scaling infrastructure is under active development.
Core Platform
85%Booking System
Online booking with location/service selection, calendar integration
Client Dashboard
Scan results, progress tracking, file storage, visit history
Admin CMS
Content management, location management, user management, email campaigns
Authentication & Security
OTP login, session management, role-based access
SEO & Marketing Automation
GA4, UTM tracking, SEO optimization, schema markup
Revenue Infrastructure
55%Marketplace (MVP)
Product listings, vendor management, Stripe Connect payments
Provider Portal
Provider dashboard, patient management, scan results delivery
Subscription Engine
Annual plans, recurring billing, plan management
Education Platform
Articles, courses, video content, author management
Affiliate & Referral System
Tracking, commission calculation, payout management
Scaling Infrastructure
25%Franchise Management System
Licensee onboarding, revenue tracking, compliance monitoring
Mobile App
iOS/Android app with booking, results, tracking
AI/ML Insights Engine
Predictive bone health models, personalized recommendations
Telemedicine Integration
Video consultations, remote monitoring, specialist matching
Enterprise B2B Platform
Corporate wellness programs, bulk booking, HR dashboards
Overall platform readiness
~55%
Team & Budget
Hiring plan & team requirements
Scaling from 8 FTE in Year 1 to 80 FTE by Year 5, with payroll growing from $780K to $8.8M as revenue per employee increases.
Year 1 (2026)
8
FTE
$780K
Year 2 (2027)
16
FTE
$1.6M
Year 3 (2028)
30
FTE
$3.2M
Year 4 (2029)
50
FTE
$5.5M
Year 5 (2030)
80
FTE
$8.8M
Year 1 (2026) — 8 FTE
$780K payroll| Role | Count | Salary Range | Department |
|---|---|---|---|
| CEO / Co-Founder | 1 | $120-150K | Executive |
| CTO / Tech Lead | 1 | $130-160K | Engineering |
| Full-Stack Developer | 1 | $110-140K | Engineering |
| Marketing Director | 1 | $100-120K | Marketing |
| Operations Manager | 1 | $70-90K | Operations |
| Clinical Coordinator | 1 | $60-80K | Clinical |
| Sales Representative | 1 | $55-70K + commission | Sales |
| Customer Success | 1 | $45-60K | Operations |
Year 2 (2027) — 16 FTE
$1.6M payroll| Role | Count | Salary Range | Department |
|---|---|---|---|
| VP of Sales | 1 | $120-150K | Sales |
| Sales Representative | 3 | $55-70K + commission | Sales |
| UX/UI Designer | 1 | $90-120K | Engineering |
| Scan Technician | 2 | $45-60K | Clinical |
| Content Manager | 1 | $60-80K | Marketing |
Year 3 (2028) — 30 FTE
$3.2M payroll| Role | Count | Salary Range | Department |
|---|---|---|---|
| Regional Manager | 3 | $80-100K | Operations |
| Franchise Support | 2 | $60-80K | Operations |
| Data Engineer | 1 | $120-150K | Engineering |
| Senior Developer | 2 | $130-160K | Engineering |
| Marketing Specialist | 3 | $55-75K | Marketing |
| Scan Technician | 3 | $45-60K | Clinical |
Year 4 (2029) — 50 FTE
$5.5M payroll| Role | Count | Salary Range | Department |
|---|---|---|---|
| COO | 1 | $150-200K | Executive |
| VP Marketing | 1 | $120-150K | Marketing |
| International Expansion Lead | 1 | $100-130K | Operations |
| Additional staff across departments | 17 | $50-120K | Various |
Year 5 (2030) — 80 FTE
$8.8M payroll| Role | Count | Salary Range | Department |
|---|---|---|---|
| CFO | 1 | $160-220K | Executive |
| VP International | 1 | $130-170K | Operations |
| Additional staff across departments | 28 | $50-130K | Various |
Revenue per Employee
$180K
Y1
$210K
Y2
$250K
Y3
$280K
Y4
$310K
Y5
Leadership
Built by operators & clinicians
A lean, focused team combining health-tech vision, medical compliance expertise, and AI-powered engineering to scale REMS diagnostics nationally.
George Bryant
Founder & Ideologist
Visionary behind HALLĒ. Conceived the REMS-first approach and drives the mission to make ultrasound bone health accessible to all.
Dr. Krystyna Shepetiuk
CEO & Medical Compliance
Medical professional overseeing clinical compliance, provider network standards, and FDA regulatory alignment for REMS technology.
Technology Team
Engineering & Product
AI-powered development pipeline building the platform — booking, dashboards, marketplace, provider ecosystem, and analytics.
Legal
Disclosures & Risk Factors
Please review the following disclosures carefully before considering any investment.
This page contains forward-looking statements about expected future performance. These are based on current expectations and involve risks and uncertainties. Actual results may differ materially. Revenue projections and return calculations are illustrative only.
Investing in early-stage companies involves substantial risk, including potential loss of your entire investment. Key risks include: limited operating history, dependence on key personnel, regulatory changes, competition, market adoption uncertainty, and general economic conditions.
Information on this page is for informational purposes only and does not constitute an offer to sell or recommendation of any security. Any offering will be made only through official documents filed with or exempt from applicable securities laws.
A SAFE is not equity and does not represent current ownership. SAFEs convert to equity at a future priced round, subject to valuation cap and discount rate. No guarantee that a conversion event will occur. SAFEs have no maturity date, bear no interest, and carry no voting rights.
Securities offerings will comply with applicable federal and state laws, including Reg CF, Reg D 506(b), and 506(c). Certain opportunities may be limited to accredited investors as defined by SEC Rule 501.
Dividend projections are illustrative estimates. Actual dividends depend on profitability, board approval, and cash flow. The company is under no obligation to pay dividends. Past performance does not guarantee future results.
Investor FAQ
Common questions
A SAFE (Simple Agreement for Future Equity) is the most common instrument for early-stage investing. Your investment converts to equity at the next priced round, typically at a 20% discount to later investors, subject to a $5M valuation cap.
In Round 1, we open a 2-year investment window (2026-2028). When the round closes, each investor's percentage is determined by their contribution relative to the total pool. The larger your contribution, the greater your stake.
Your ownership equals your investment divided by the total angel pool at close. This determines your proportional allocation in Round 2 and equity stake at SAFE conversion. The 20% discount means you get equity at 20% lower valuation than Round 2 investors.
Dividends apply only to Rounds 2 and 3 (8% and 6% respectively). Round 1 (SAFE) does not include dividends. Dividends accrue annually and are paid when profitable and board-approved.
At IPO (targeted 2030), all preferred stock converts to common stock 1:1. Investors can sell on the public market. Early investors benefit from significantly lower entry valuations.
Securities are generally illiquid. Under Reg CF, SAFEs have a 1-year holding period. There is no secondary market. Investors should expect to hold 5-10 years.
Round 1: $5,000 minimum. Round 2: $10,000. Round 3: $50,000. Non-accredited investors in Round 1 are subject to annual limits under Reg CF.
The calculator shows Pessimistic (8%), Average (14%), and Optimistic (24%) CAGR. S&P 500 averages ~10%. Strong health-tech can achieve 15-25%+. Only invest what you can afford to lose.
Join the Future
Ready to invest in bone health?
Join our angel round and become part of the REMS revolution. Early investors receive the most favorable terms and exclusive access to future rounds.